Oncolin Therapeutics, Inc.
Oncolin Therapeutics, Inc. (Oncolin Therapeutics), formerly Edgeline Holdings, Inc. operates in the healthcare division through its subsidiary Intertech Bio Corporation. The company is an early stage development company engaged in the development of products to treat cancer, medical disorders related to immune system, and other infectious diseases. Oncolin Therapeutics entered into optional agreements with the University of Texas MD Anderson Cancer Center and pharmaceutical research institute of Warsaw, Poland to facilitate and improve its research opportunities. Its research activities are mainly focused on developing drug candidates that interfere with the key mechanisms of tumor progression. The company has several products in its pipeline undergoing clinical trails that functions more effectively on solid tumors and cancer causing agents. Oncolin Therapeutics is headquartered in Texas, the US.